CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-16). The draft was written by AI, the existence of all 1 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 380 · Search date 2026-07-16 · Methodology v0.6

Blackcurrant anthocyanins,
does it really help with VDT-related eye fatigue and dark adaptation?

30-Second Summary
C
Evidence Grade C · 40 · Safety unknown
The acute signal from a 50 mg standardized concentrate cannot be generalized to generic blackcurrant products or vision restoration
What the
research shows
This claim receives C because a small double-blind crossover trial of standardized blackcurrant anthocyanoside concentrate found signals for the dark-adaptation threshold and selected subjective eye-fatigue symptoms after a 50 mg dose. Dark adaptation involved only 12 participants and the VDT refraction and symptom study 21; the between-condition refraction result was borderline null at p=0.064. Independent replication and clinical vision outcomes are absent.
What the
ads claim
Claims expand to 'better night vision,' 'screen protection,' and 'focus recovery,' while whole blackcurrant powder is treated as equivalent to standardized anthocyanin concentrate. Trials of other berries or antioxidant combinations are also cited as if they were blackcurrant evidence.
*

Useful facts when choosing a product

  • Blackcurrant powders, juices, concentrates, and anthocyanin-labeled capsules are sold in Korea.
  • The direct eye study used single doses of 12.5-50 mg anthocyanosides, with the main signal at 50 mg.
  • Whole-fruit powder weight is not the same as anthocyanin content, so milligram labels cannot be compared directly.
  • No major short-term safety signal emerged, but long-term ocular efficacy and safety data for concentrated extracts are limited.
Gap Measurement · Verdict 380 · C 40
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2000 Nakaishi crossover study compared 12.5, 20, and 50 mg in a 12-person dark-adaptation experiment and reported a pre-to-post threshold change at 50 mg. In a 21-person VDT experiment, the between-condition refraction result was p=0.064, while selected eye and lower-back questionnaire symptoms improved. Many later eye-fatigue trials tested bilberry, maqui berry, or combinations containing lutein and astaxanthin; they were not pooled as standalone blackcurrant evidence.

02

Why this is classified as C (40)

The direct standalone study is recognized, but it is one paper from 2000 with only 12 participants for dark adaptation and 21 for VDT outcomes, borderline-null refraction at p=0.064, subjective eye-fatigue findings, and no independent replication, yielding C with 40 points.

Counterpoint. The acute dark-adaptation signal merits exploration, but a large independent trial is needed for sustained VDT symptoms and clinically meaningful visual function.

Rejudgment record. Reassessment (cross-check reflected) — Recognized the standalone human trial but applied a C ceiling for tiny samples, surrogate and subjective outcomes, p=0.064 refraction, and absent independent replication

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved dark-adaptation thresholdCA 50 mg signal in a 12-person single-dose experiment
VDT-related eye fatigue and refractive changeCSelected subjective symptoms improved in 21 people, while refraction was p=0.064

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Nakaishi et al. (2000), dark adaptationDouble-blind placebo-controlled crossover dose study12Ingredient research linked to Meiji SeikaDark-adaptation thresholdLower pre-to-post threshold at 50 mg; tiny sampleKey
Nakaishi et al. (2000), VDT taskDouble-blind placebo-controlled crossover trial21Ingredient research linked to Meiji SeikaPost-VDT refraction and eye-fatigue questionnaireRefraction p=0.064; selected subjective symptoms improvedKey
§

Receipt — 1 References

All 1 cited sources were verified for existence at the original page (as of 2026-07-16).

Nakaishi H, Matsumoto H, Tominaga S, Hirayama M. Effects of black current anthocyanoside intake on dark adaptation and VDT work-induced transient refractive alteration in healthy humans. Altern Med Rev. 2000;5(6):553-562. PMID: 11134978.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none

Cite this verdict

Blackcurrant anthocyanins x VDT-related eye fatigue and dark adaptation Evidence Grade C card
[Chamgap] Blackcurrant anthocyanins x VDT-related eye fatigue and dark adaptation — Evidence Grade C·40. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/blackcurrant-anthocyanins-vdt-eye-fatigue-dark-adaptation/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.